Last reviewed · How we verify
Cellgram-LC
Cellgram-LC is an allogeneic mesenchymal stem cell therapy that modulates immune responses and promotes tissue repair through paracrine signaling.
Cellgram-LC is an allogeneic mesenchymal stem cell therapy that modulates immune responses and promotes tissue repair through paracrine signaling. Used for Graft-versus-host disease (GVHD), Inflammatory bowel disease.
At a glance
| Generic name | Cellgram-LC |
|---|---|
| Also known as | Autologous bone marrow-derived mesenchymal stem cell |
| Sponsor | Pharmicell Co., Ltd. |
| Drug class | Allogeneic mesenchymal stem cell therapy |
| Modality | Biologic |
| Therapeutic area | Immunology / Regenerative Medicine |
| Phase | Phase 3 |
Mechanism of action
Cellgram-LC consists of bone marrow-derived mesenchymal stem cells (MSCs) that exert immunomodulatory and anti-inflammatory effects through the secretion of bioactive molecules including cytokines and growth factors. These cells are designed to reduce pathological inflammation, promote angiogenesis, and support tissue regeneration in damaged tissues. The therapy leverages the inherent capacity of MSCs to migrate to sites of injury and modulate both innate and adaptive immune responses.
Approved indications
- Graft-versus-host disease (GVHD)
- Inflammatory bowel disease
Common side effects
- Infusion-related reactions
- Infection
- Fever
Key clinical trials
- Clinical Trial to Evaluate the Efficacy and Safety of Cellgram-LC Administration in Patients With Alcoholic Cirrhosis (PHASE3)
- Long-term Follow-up of Patients With Alcoholic Liver Cirrhosis Who Had Administered Cellgram-LC in PMC-P-07 Study (NA)
- Study to Evaluate Hepatic Artery Injection of Autologous Human Bone Marrow-Derived MSCs in Patients With Alcoholic LC (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |